Overview of Avicin

Property	Description
Active ingredient	Ofloxacin (Monotherapy)
Forms	Oral tablet, Oral syrup, IV solution, Ophthalmic drops
Pharmacological class	Fluoroquinolone Antibiotic
Common use	Resolution of bacterial infections
Origin	Synthetic

What Type of Medicine is Avicin (Ofloxacin)?

Avicin is a prescription-only drug defined by its active ingredient, Ofloxacin, which is a synthetic broad-spectrum antimicrobial agent. This medicine belongs to the fluoroquinolone pharmacological class, specifically categorized as a second-generation quinolone antibiotic. Clinical literature consistently supports the potency of this class against a wide range of bacterial species, which is the foundational characteristic for its utility in medicine. This broad-spectrum capability is highly valued for treating infections where the causative organism may be varied, such as those typically found in urinary or respiratory tracts.

Composition and Forms: Single-Ingredient Ofloxacin

The fundamental composition of Avicin centers on the single active ingredient, Ofloxacin, generally supplied as a monotherapy. Ofloxacin is manufactured in several distinct pharmaceutical preparations to facilitate various routes of administration, including the standard oral tablet and a liquid oral syrup, as well as a sterile solution for intravenous administration and a topical ophthalmic solution. The existence of these diverse dosage forms allows medical professionals to select the specific preparation necessary for targeted or systemic treatment, distinguishing its utility from single-form medications.

The General Purpose of Avicin's Antimicrobial Action

The general purpose of Avicin is to achieve the resolution of underlying bacterial infections by exerting a definitive bactericidal effect. Its action is confirmed to rely on inhibiting bacterial DNA processes, which is the exact mechanism that results in the death of the pathogenic bacteria. This direct physiological action ensures that the drug addresses the root cause of the illness by eliminating the source of the infection, a principle clinically recognized for resolving illnesses that require robust antimicrobial intervention.

What side effects are possible with Avicin?

Possible Side Effects and Safety Information

Avicin is associated with a risk of serious, disabling, and potentially permanent side effects involving the tendons, muscles, joints, nerves, and central nervous system. Regulatory agencies, including the FDA and EMA, have placed significant restrictions on its use and require prominent warnings to inform patients and healthcare providers of these risks. These adverse reactions can occur together in the same patient and may manifest hours to weeks after starting treatment, sometimes persisting for months or years after discontinuation.

Serious and Clinically Significant Adverse Reactions

The most serious documented side effects include:

Tendinitis and Tendon Rupture: Inflammation or tearing of tendons, which can occur during or even months after stopping treatment. This risk is higher in the elderly, those with kidney impairment, transplant recipients, and patients taking systemic corticosteroids.
Peripheral Neuropathy: Nerve damage outside the brain and spinal cord, resulting in pain, burning, tingling, numbness, or weakness in the arms or legs.
Central Nervous System Effects: These include psychiatric reactions (such as anxiety, confusion, depression, hallucinations, and suicidal thoughts) and seizures.
Other Serious Events: Exacerbation of muscle weakness in patients with myasthenia gravis, prolongation of the QT interval (a heart rhythm abnormality), serious hypersensitivity reactions, and severe diarrhea associated with Clostridium difficile.

Common Side Effects

More common reactions may include nausea, diarrhea, headache, dizziness, and trouble sleeping. These are typically less severe than the reactions listed above.

Safety Monitoring

Due to the potential for irreversible harm, treatment is officially recommended to be stopped immediately at the first sign of tendon pain, inflammation, or symptoms of neuropathy (such as numbness or pins and needles). The drug is to be reserved for use in patients who have no alternative treatment options for certain less severe infections.

Overdose and Emergency Response

Overdose and when to seek help

Overdose on Avicin (Ofloxacin) is formally described in regulatory labeling as potentially leading to severe clinical signs and systemic toxicity. Documented central nervous system (CNS) manifestations include convulsions, tremors, and symptoms associated with increased intracranial pressure, alongside behavioral signs such as confusion, lightheadedness, and restlessness. Acute exposure has also been linked to motor impairments like ataxia and prostration.

The official profile notes severe, life-threatening outcomes, including ventricular arrhythmias and Torsades de pointes, as well as the potential for acute renal failure and severe liver injury. Regulators mandate that individuals must seek immediate medical attention following a suspected overdose.

Urgent medical help is required upon observing signs like a rapid heartbeat, acute difficulty in breathing (dyspnoea), new-onset heart palpitations, or swelling suggestive of angioedema. Management is defined as symptomatic and supportive treatment, including ensuring proper hydration and observation. The official labeling states no specific antidote is known and notes that ECG monitoring is recommended due to the cardiac risks. Population-specific warnings highlight increased risk of tendon rupture in older patients and those with transplants.

Therapeutic Uses of Avicin

Avicin is applied across therapeutic domains where additional symptomatic support is needed, primarily focusing on easing periods of heightened discomfort and contributing to functional stability. The medication's therapeutic relevance is informed by research on its components.

It is commonly used to help with symptoms related to physical discomfort, heightened physiological activity, and noticeable functional strain. This applies to conditions marked by episodic or fluctuating manifestations and situations involving acute or unstable symptom patterns. Avicin supports patients during difficult episodes by easing distress and is considered relevant for managing these symptoms, particularly when they interfere with routine activities.

Quick Fact: Relief for Heightened Symptoms

Avicin is often used when symptoms intensify and short-term supportive relief is needed, helping to maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Avicin (Ofloxacin) — Official Regulatory Information

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults (18 years and older) who do not have any contraindicating or special caution conditions.
Populations for whom use is not recommended (if applicable)	Patients for whom other commonly recommended antibiotics are appropriate for the treatment of uncomplicated infections, per regulatory restrictions.
Populations for whom use is contraindicated	Patients with a history of hypersensitivity to Ofloxacin, other quinolone antibacterials, or any excipients.
Age-related eligibility rules	Contraindicated in children and growing adolescents. Special caution is required for patients over 60 years due to increased risk of tendon injury.
Condition-specific eligibility rules	Contraindicated in patients with a history of epilepsy or an existing Central Nervous System (CNS) disorder with a lowered seizure threshold.
Pregnancy and lactation eligibility status (if explicitly documented)	Contraindicated in both pregnant women and breastfeeding women.
Eligibility-related restrictions	Contraindicated in patients with a history of tendon disorders related to previous fluoroquinolone administration. Special caution is required in patients with renal impairment or severe hepatic dysfunction (liver disease).

Official Eligibility Statements:

Avicin (Ofloxacin) is contraindicated in patients with a known hypersensitivity to the drug or any other fluoroquinolone antibacterial.
The systemic use of Ofloxacin is contraindicated in children, growing adolescents, pregnant women, and breastfeeding women.
The medicine is contraindicated in patients with a history of epilepsy, CNS disorders with a lowered seizure threshold, or a history of tendon disorders related to fluoroquinolone use.
Special caution is advised for the elderly, patients with renal impairment, or patients receiving corticosteroids.

Connection to the Overall Eligibility Profile Regulatory documents establish the eligible user base by imposing absolute contraindications across specific disease states, prior adverse reactions, and key developmental and reproductive populations. The profile is completed by defining populations where use is conditional, requiring special caution due to increased risk factors (e.g., age, renal function), thereby strictly limiting the eligible user base.

What should I know about interactions with other medicines?

Avicin Interactions with other medicines and products

The official regulatory documents for Avicin (Ofloxacin) detail specific drug and product interactions classified by their effects on drug exposure and shared physiological risks.

Absorption and Timing Requirements

Co-administration with agents containing multivalent cations can significantly reduce Avicin’s systemic exposure due to the formation of non-absorbable chelates. This includes antacids (magnesium, aluminum), sucralfate, and preparations containing iron or zinc. To manage this effect, the official label mandates that Avicin must be administered at least two hours before or two hours after taking these products.

Pharmacokinetic and Metabolic Effects

Ofloxacin is documented to alter the plasma levels of certain co-administered drugs. It can interfere with the clearance of Theophylline and Caffeine, potentially leading to elevated plasma concentrations of these substances. Conversely, drugs like Probenecid may reduce Ofloxacin's clearance through the inhibition of renal tubular secretion, thereby increasing Avicin’s own systemic exposure.

Additive Pharmacodynamic Risks

Interactions based on shared physiological effects include the additive risk of QT interval prolongation when combined with Class IA and III antiarrhythmics. There is also an increased potential for CNS stimulation or seizures when Ofloxacin is combined with certain NSAIDs, such as Fenbufen. Co-use with antidiabetic agents (insulin or oral agents) may result in documented episodes of dysglycemia (hypo- or hyperglycemia). The combined use of Ofloxacin and corticosteroids is associated with an increased risk of tendon damage, a risk that is explicitly heightened in patients over 60 years of age.

Mechanism of Action

Molecular Mechanism of Avicin (Ofloxacin)

Avicin exerts its effect through a specific pharmacodynamic mechanism that interferes with essential bacterial processes. The molecule acts as a topoisomerase poison, meaning it selectively targets and inhibits two critical microbial enzymes: DNA gyrase (Topoisomerase II) and Topoisomerase IV. These enzymes are vital for managing the topological structure of bacterial DNA, including supercoiling for replication and separation of daughter chromosomes during cell division.

The drug binds to the transient complex formed between the enzyme and the cleaved bacterial DNA. This interaction stabilizes the complex after the DNA strands have been cut but prevents the crucial DNA resealing, leading to the rapid accumulation of lethal double-strand DNA breaks . This damage triggers an irreversible, self-destruct sequence known as the bactericidal cascade. The resulting definitive eradication of susceptible pathogenic bacteria is the sole physiological consequence of the mechanism. Its effect is constrained by Target-Mediated Resistance and Efflux Pump Overexpression, which prevent the drug from achieving lethal concentrations or binding affinity at its targets.

Dosage and Administration Information

Official Administration Guidelines for Avicin (Ofloxacin)

Avicin is administered through several officially approved routes depending on the intended use: Oral (tablet or syrup) and Intravenous (IV) Infusion are for systemic treatment, while Topical Ophthalmic (eye drops) and Topical Otic (ear drops) are for localized use.

Systemic Dosing and Schedule

Systemic administration typically involves unit doses ranging from 200 mg to 400 mg. The total daily dosage for most indications should not exceed 800 mg.

Frequency: Daily doses of 400 mg or less may be administered as a single dose. However, if the total daily dose is greater than 400 mg, it must be divided into two equal portions and administered approximately every 12 hours.
Administration Conditions: Oral tablets or syrup may be taken with or without food. The IV solution requires proper dilution before use and must be administered slowly by infusion over 60 minutes.

Population-Specific Dosing and Constraints

Dosing requires modification based on a patient’s organ function. Patients with impaired renal or hepatic function may require a dose reduction or an extension of the dosing interval to once every 24 hours, as specified in the official labeling. Systemic use of Avicin is generally not recommended for children and adolescents under 18 years of age due to growth considerations. Treatment duration is condition-dependent and must not exceed two months.

Handling a Missed Dose

If a systemic dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the user should only take the next dose and must not double the dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Avicin (Ofloxacin)

The research supporting the use of Ofloxacin focuses on its activity against specific bacterial infections across various body systems. This overview describes the types of clinical studies that have been conducted and the nature of the outcomes examined, remaining neutral on individual patient results or recommendations.

Evidence for Systemic Bacterial Infections

Clinical research for the systemic (oral and intravenous) use of Ofloxacin primarily consists of Randomized Controlled Trials (RCTs) and various Therapeutic Comparative Studies. These trials explored the drug's use in adult patients across several infection types where the cause is suspected or confirmed to be susceptible bacteria.

Research on Urinary Tract Infections (UTIs)

Research has been conducted on the use of Ofloxacin for both uncomplicated and complicated UTIs. Studies for this indication often involve comparative trials where Ofloxacin was evaluated against other established antibacterial agents. Researchers designed these studies to measure two key outcomes: the bacteriological elimination (of the specific disease-causing organism) and the clinical response, which tracks the observed changes in physical signs and symptoms over a defined time interval.

Research on Lower Respiratory and Skin Infections

RCTs and Open Prospective Trials have also explored Ofloxacin's role in infections of the lower respiratory tract, such as certain types of community-acquired pneumonia, as well as uncomplicated skin and skin structure infections. The research highlights measured changes in clinical endpoints when Ofloxacin was evaluated against confirmed susceptible strains. For these indications, the evidence quality varies across studies, and there is limited recent comparative evidence against some of the newer agents currently available.

Evidence for Locally Applied Infections (Ophthalmic and Otic)

For infections requiring targeted application, Ofloxacin has been evaluated in Noninferiority Randomized Studies that compared the topical ophthalmic or otic solution to other local treatments or a non-active vehicle. Research was conducted specifically for conditions like bacterial conjunctivitis, corneal ulcers, and certain ear infections.

What is Still Uncertain About Avicin Research

Authoritative sources suggest that the evidence landscape, while extensive for established uses, is not without uncertainty. One primary concern that research continues to examine relates to antimicrobial resistance patterns. Data show patterns related to resistance that are relevant to the generalizability of older study results. Furthermore, while Ofloxacin was studied for several conditions, information remains limited regarding outcomes in patients where the responsible bacteria have developed resistance.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Avicin (FAQ)

Q: Can I take Avicin if I'm taking a multivitamin?

Official guidance states that products containing multivalent cations, such as iron, zinc, or calcium often found in multivitamins or antacids, can significantly reduce the absorption of Avicin into the body. To manage this effect, Avicin is officially advised to be taken at least two hours before or two hours after consuming these types of products.

Q: Are there any known issues when taking Avicin with common pain relievers like ibuprofen?

Regulatory warnings indicate that Avicin belongs to a class of medicines (fluoroquinolones) that carries a documented, although uncommon, risk of increasing central nervous system stimulation or seizures when used at the same time as certain non-steroidal anti-inflammatory drugs (NSAIDs). If an NSAID is being used, the full medical labeling should be reviewed for potential interactions.

Q: Is there a generic version of Avicin available?

Yes, Avicin is the brand name for the medicine whose active ingredient is Ofloxacin. Ofloxacin is the established generic name for this particular antimicrobial agent.

Q: How long can I typically expect the effects of Avicin to last?

Official pharmacokinetic information indicates how long the drug remains in the body. The mean elimination half-life of Ofloxacin, which is the time required for the body to remove half of the medicine's concentration, is typically described as being between 8 to 9 hours.

Q: What is the most common reason people are prescribed Avicin?

Because of its safety profile, regulatory agencies advise that this medicine be reserved for use only in patients who have no alternative treatment options for specific, less severe bacterial infections. This regulatory status means its use is intentionally restricted when other treatments are available.

Q: What happens if I stop taking Avicin suddenly?

Regulatory guidance instructs individuals not to stop taking the drug without consulting a healthcare provider, unless they are advised to do so due to experiencing serious side effects. Discontinuing antimicrobial treatment too soon is associated with the potential development of antimicrobial resistance.

Q: What should I do if I think Avicin is causing a side effect?

Official safety information advises discontinuing the medication immediately and seeking emergency medical help at the first sign of certain serious reactions, such as tendon pain, nerve symptoms (like numbness or tingling), or severe central nervous system effects. For less severe reactions, official documentation suggests that a healthcare provider should be consulted.

Q: Is it okay to drive while taking Avicin?

Regulatory documents advise that individuals should avoid driving or operating heavy or hazardous machinery until the user knows how the medication affects them. This caution is stated because the drug has the potential to cause dizziness or impair coordination and reactions.

Q: Is the research on Avicin recent, or has it been around for a long time?

The active ingredient, Ofloxacin, was first approved by the U.S. FDA in 1990, indicating a long history of use. However, regulatory agencies have issued multiple updated safety warnings and new use limitations for this class of antibiotics since 2008, showing that the safety guidance is subject to ongoing review.

Q: Can I use Avicin if I have high blood pressure?

Regulatory documentation notes that having high blood pressure is a condition that may require special consideration or caution during treatment. This caution is related to the documented risks of heart rhythm abnormalities and aortic-related side effects associated with the drug's class.

Q: How quickly is Avicin removed from the body?

Official pharmacokinetic data indicates that the medicine is primarily removed through the kidneys. Between 65% and 80% of an administered oral dose of the medicine is described as being excreted unchanged via the kidneys within 48 hours of dosing.

Q: Are there known concerns about taking Avicin with alcohol, even in small amounts?

The official prescribing information states that there are no known interactions documented between this medicine and alcohol.

Q: What if I accidentally took two doses of Avicin?

Symptoms of overdose that have been reported include reactions such as drowsiness, nausea, dizziness, confusion, and slurred speech. If an overdose is suspected, users are instructed to seek emergency medical help immediately.

Q: Can Avicin affect birth control pills?

While the systematic failure risk is considered low, the medicine has the theoretical potential to alter intestinal bacteria, which is part of the process for the body to absorb and recycle estrogen from oral hormonal contraceptives. Patients are advised to discuss this potential interaction with their healthcare provider.

Q: Are there any specific warnings for people who operate heavy machinery while taking Avicin?

Official documentation advises avoiding the operation of hazardous machinery until the user knows how the medication affects them. This warning is based on the risk that the drug may cause dizziness or impair coordination and reactions.

Q: Is it true that Avicin can make you more sensitive to the sun?

Yes, official safety documentation confirms that the drug is documented to cause photosensitivity (an increased sensitivity to sunlight or ultraviolet light). Patients are officially advised to avoid unnecessary sun exposure and to use protective measures like sunscreen while undergoing treatment.

Q: How long has Avicin been approved for use?

The active ingredient, Ofloxacin, was first approved by the U.S. FDA in December 1990. Its use has been subject to continuous regulatory review since that time.

How should Avicin be stored and disposed of?

How to Store and Dispose of Avicin

Official regulatory guidelines for Avicin (Ofloxacin) emphasize strict control of the storage environment to maintain the stability of this medicine.

Storage Requirements

Temperature: Store at controlled room temperature (typically 20 C to 25 C), protecting the medication from excessive heat.
Environment: The product must be kept from freezing and stored away from direct light and moisture.
Container: Keep Avicin in the container it was dispensed in, ensuring it remains tightly closed.
Safety: A mandatory requirement is to keep all medication out of the sight and reach of children.

Disposal Instructions

Do not keep outdated medicine or medicine that is no longer needed. The official procedure for discarding unused Avicin is to consult a healthcare professional or pharmacist for proper guidance on disposal methods.

Avicin